The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
Open accessAbstract
BACKGROUND: Clinical prognostic groupings for localised prostate cancers are imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices in prostate cancer to improve risk stratification and complement clinical prognostic factors. METHODS: We used DNA-based indices alone or in combination with intra-prostatic hypoxia measurements to develop four prognostic indices in 126 low-risk to intermediate-risk patients (Toronto cohort) who will receive image-guided radiotherapy. We validated these indices in two independent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] cohort) and 117 (Cambridge cohort) radical prostatectomy specimens from low-risk to high-risk patients. We applied unsupervised and supervised machine learning techniques to the copy-number profiles of 126 pre-image-guided radiotherapy diagnostic biopsies to develop prognostic signatures. Our primary endpoint was the development of a set of prognostic measures capable of stratifying patients for risk of biochemical relapse 5 years after primary treatment. FINDINGS: Biochemical relapse was associated with indices of tumour hypoxia, genomic instability, and genomic subtypes based on multivariate analyses. We identified four genomic subtypes for prostate cancer, which had different 5-year biochemical relapse-free survival. Genomic instability is prognostic for relapse in both image-guided radiotherapy (multivariate analysis hazard ratio [HR] 4·5 [95% CI 2·1-9·8]; p=0·00013; area under the receiver operator curve [AUC] 0·70 [95% CI 0·65-0·76]) and radical prostatectomy (4·0 [1·6-9·7]; p=0·0024; AUC 0·57 [0·52-0·61]) patients with prostate cancer, and its effect is magnified by intratumoral hypoxia (3·8 [1·2-12]; p=0·019; AUC 0·67 [0·61-0·73]). A novel 100-loci DNA signature accurately classified treatment outcome in the MSKCC low-risk to intermediate-risk cohort (multivariate analysis HR 6·1 [95% CI 2·0-19]; p=0·0015; AUC 0·74 [95% CI 0·65-0·83]). In the independent MSKCC and Cambridge cohorts, this signature identified low-risk to high-risk patients who were most likely to fail treatment within 18 months (combined cohorts multivariate analysis HR 2·9 [95% CI 1·4-6·0]; p=0·0039; AUC 0·68 [95% CI 0·63-0·73]), and was better at predicting biochemical relapse than 23 previously published RNA signatures. INTERPRETATION: This is the first study of cancer outcome to integrate DNA-based and microenvironment-based failure indices to predict patient outcome. Patients exhibiting these aggressive features after biopsy should be entered into treatment intensification trials. FUNDING: Movember Foundation, Prostate Cancer Canada, Ontario Institute for Cancer Research, Canadian Institute for Health Research, NIHR Cambridge Biomedical Research Centre, The University of Cambridge, Cancer Research UK, Cambridge Cancer Charity, Prostate Cancer UK, Hutchison Whampoa Limited, Terry Fox Research Institute, Princess Margaret Cancer Centre Foundation, PMH-Radiation Medicine Program Academic Enrichment Fund, Motorcycle Ride for Dad (Durham), Canadian Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, the tumor microenvironment has also been shown to induce tumor heterogeneity and promote the growth of a tumor itself [8,9].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Punctuated Evolution of Prostate Cancer Genomes
Baca, S. C., Prandi, D., Lawrence, M. S., Mosquera, J. M., Romanel, A., Drier, Y., Park, K., Kitabayashi, N., MacDonald, T. Y., Ghandi, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.021 · Cited by 1,320
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Self-citationMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Yue, S., Li, J., Lee, S.-Y., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., Ratliff, T. L., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.019 · Cited by 929
Heidenreich, A., Joaquim Bellmunt, B., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 875
Cited by
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
“Although certain primary prostate cancer alterations or signatures have prognostic clinical significance (Hieronymus et al., 2014; Lalonde et al., 2014), the therapeutic impact of primary prostate cancer genomic events has not yet been realized.”
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
“…also have varying degrees of DNA copy-number alteration; indolent and low-Gleason tumors have few alterations, whereas more aggressive primary and metastatic tumors have extensive burdens of copy-number alteration genome-wide (Taylor et al., 2010, Hieronymus et al., 2014, Lalonde et al., 2014).”
BackgroundSelf-citationClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
“…(Bolli et al., 2014); lung adenocarcinomas (de Bruin et al., 2014; Zhang et al., 2014); prostate (Gundem et al., 2015; Ju et al., 2014); bladder (Lamy et al., 2016); colorectal adenocarcinomas (Uchi et al., 2016); liver hepatocellular carcinoma (Xue et al., 2016); esophageal squamous cell…”
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Self-citationMolecular landmarks of tumor hypoxia across cancer types
Bhandari, V., Hoey, C., Liu, L. Y., Lalonde, E., Ray, J., Livingstone, J., Lesurf, R., Shiah, Y.-J., Vujcic, T., Huang, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0318-2 · Cited by 678
Self-citation
Metadata
- Authors
- Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., Zafarana, G., Warren, A. Y., Meng, X., Thoms, J., Grzadkowski, M. R., Berlin, A., Have, C. L., Ramnarine, V. R., Yao, C. Q., Malloff, C. A., Lam, L. L., Xie, H., Harding, N. J., Mak, D. Y. F., Chu, K. C., Chong, L. C., Sendorek, D. H., P'ng, C., Collins, C. C., Squire, J. A., Jurisica, I., Cooper, C., Eeles, R., Pintilie, M., Dal Pra, A., Davicioni, E., Lam, W. L., Milosevic, M., Neal, D. E., van der Kwast, T., Boutros, P. C., & Bristow, R. G.
- Affiliations
- Ontario Institute for Cancer Research (CA)
- University of Miami (US)
- University Health Network (CA)
- University of Cambridge (GB)
- Addenbrooke's Hospital (GB)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Universidade de São Paulo (BR)
- University of East Anglia (GB)
- National Health Service (GB)
- University of Toronto (CA)
- Corresponding author
- Bristow, Robert G
- ORCID
- Lalonde, Emilie
- Ishkanian, Adrian S
- Sykes, Jenna
- Fraser, Michael
- Erho, Nicholas
- Dunning, Mark J
- Halim, Silvia
- Lamb, Alastair D
- Moon, Nathalie C
- Zafarana, Gaetano
- Warren, Anne Y
- Grzadkowski, Michal R
- Ramnarine, Varune R
- Harding, Nicholas J
- Chong, Lauren C
- Sendorek, Dorota H
- Collins, Colin C
- Squire, Jeremy A
- Eeles, Rosalind
- Pintilie, Melania
- Davicioni, Elai
- Lam, Wan L
- Milosevic, Michael
- Neal, David E
- Boutros, Paul C
- Bristow, Robert G
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 15
- Issue
- 13
- Pages
- 1521-1532
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2158872144
- Semantic Scholar
- 378b92545e4328ee0569fb7c09dcf221a8d05054
- Cited by
- 342
- References
- 36
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 26 · 2023: 24 · 2022: 30 · 2021: 40 · 2020: 29 · 2019: 31 · 2018: 38 · 2017: 35 · 2016: 39 · 2015: 22 · 2014: 2
- FWCI
- 26.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- The Lancet Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Funders
- Prostate Cancer Canada and is funded by the Movember Foundation (grant number RS2014-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- prostate cancer, biochemical recurrence, tumor microenvironment, intratumoral hypoxia, genomic instability, copy number profiles, genomic subtypes, risk stratification, image-guided radiotherapy, radical prostatectomy, prognostic score, localized prostate cancer, machine learning prediction
- MeSH terms
- DNA, Neoplasm, Follow-Up Studies, Humans, Male, Neoplasm Recurrence, Local, Prognosis, Prostatic Neoplasms, Retrospective Studies, Time Factors, Biomarkers, Tumor, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71021-6
- The paper
- Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., Zafarana, G., Warren, A. Y., Meng, X., Thoms, J., Grzadkowski, M. R., Berlin, A., Have, C. L., Ramnarine, V. R., Yao, C. Q., . . . Bristow, R. G. (2014). Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71021-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.